الفهرس | Only 14 pages are availabe for public view |
Abstract It is estimated that approximately 120-130 million individuals, i.e. 3% of the world population, are chronically infected with HCV. Egypt has the highest worldwide The current study included 85 Egyptian hepatitis C patients 31 females (36.5%) and 54 males (63.5%). All patients in the study signed written informed consent. They aged between 18 to 60 years with mild changes in the liver biopsy and with more than portal fibrosis. Patients with compensated cirrhosis (Child A) were included if there were no varices. All of the patients fulfilled the inclusion criteria applied by viral hepatitis of Egyptian Ministry of Health, Egypt. The study protocol was approved by the Ethical Review Committee (ERC) of Faculty of Medicine ,University of Benha and by National Committee for control of viral hepatitis of Egyptian Ministry of Health, Egypt. from 85 patients, 74 patients responded to standard therapy, i.e. had a sustained virological response after 12 weeks of treatment (SVR12), while 11 patients (9 males and 2 females) did not respond to the therapy (non-SVR).The study investigated the possible effect of the following on the treatment response: HLA class II alleles (DRB1*13, DRB1*07and DQB1*02), IL-10 level before starting the treatment, liver histopathological status by liver biopsy assessment, body mass index (BMI), presence of antischistosoma antibodies and some laboratory parameters including AST, ALT, total bilirubin, blood glucose, TSH, AFP, WBCs count, Hb, blood platelets count and creatinine. Blood samples were drawn at baseline from the beginning of the treatment. Baseline characteristics of subjects included clinical history, physical examination, body mass index (BMI) were taken. |